Back to Search
Start Over
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin
- Source :
- Diabetes, Obesity & Metabolism
- Publication Year :
- 2018
- Publisher :
- WILEY, 2018.
-
Abstract
- The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin plus metformin was compared in a post-hoc analysis of 3 randomized trials of sequential or concomitant add-on of dapagliflozin and saxagliptin to metformin. In the concomitant add-on trial, patients with type 2 diabetes on stable metformin received dapagliflozin 10 mg/d plus saxagliptin 5 mg/d. In sequential add-on trials, patients on metformin plus either saxagliptin 5 mg/d or dapagliflozin 10 mg/d received dapagliflozin 10 mg/d or saxagliptin 5 mg/d, respectively, as add-on therapy. After 24 weeks, incidences of adverse events and serious adverse events were similar between triple and dual therapy and between concomitant and sequential add-on regimens. Urinary tract infections were more common with sequential than with concomitant add-on therapy; genital infections were reported only with sequential add-on of dapagliflozin to saxagliptin plus metformin. Hypoglycaemia incidence was
- Subjects :
- Male
endocrine system diseases
Endocrinology, Diabetes and Metabolism
Adamantane
Type 2 diabetes
Saxagliptin
law.invention
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Randomized controlled trial
Glucosides
law
030212 general & internal medicine
Dapagliflozin
Brief Report
DPP‐4 inhibitor
Dipeptides
Middle Aged
DOUBLE-BLIND TRIAL
Metformin
Treatment Outcome
Tolerability
Drug Therapy, Combination
Female
type 2 diabetes
Life Sciences & Biomedicine
SGLT‐2 inhibitor
medicine.drug
medicine.medical_specialty
Urology
TYPE-2 DIABETES-MELLITUS
030209 endocrinology & metabolism
EVENTS
03 medical and health sciences
Endocrinology & Metabolism
Double-Blind Method
DPP-4 inhibitor
SGLT-2 inhibitor
dapagliflozin
metformin
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Benzhydryl Compounds
Adverse effect
Sodium-Glucose Transporter 2 Inhibitors
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
Science & Technology
business.industry
nutritional and metabolic diseases
medicine.disease
EFFICACY
Hypoglycemia
chemistry
Diabetes Mellitus, Type 2
PLUS METFORMIN
Concomitant
Brief Reports
business
Subjects
Details
- Language :
- English
- ISSN :
- 15421546
- Database :
- OpenAIRE
- Journal :
- Diabetes, Obesity & Metabolism
- Accession number :
- edsair.doi.dedup.....1088146dd05115bef5b32a1a3362bb43